Matching articles for "deruxtecan"
In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)
Fam-trastuzumab deruxtecan-nxki ( Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of…
Med Lett Drugs Ther. 2023 Apr 3; 65(1673):e60-1 doi:10.58347/tml.2023.1673f
Fam-trastuzumab deruxtecan-nxki ( Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of response,1 has been granted regular approval for treatment of adults with unresectable or metastatic HER2-positive breast cancer who received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed recurrence during or within 6 months of completing treatment.
